Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel

Adams, 1987, Role of platelets in atherogenesis: Relevance to coronary arterial restenosis after angioplasty, Cardiovasc Clin, 18, 49 Angiolillo, 2007, Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives, J Am Coll Cardiol, 49, 1505, 10.1016/j.jacc.2006.11.044 Angiolillo, 2005, Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease, Thromb Haemost, 116, 491 Angiolillo, 2006, Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel, Arterioscler Thromb Vasc Biol, 26, 1895, 10.1161/01.ATV.0000223867.25324.1a Angiolillo, 2004, High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability, Eur Heart J, 25, 1903, 10.1016/j.ehj.2004.07.036 Angiolillo, 2007, Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study, Circulation, 115, 708, 10.1161/CIRCULATIONAHA.106.667741 Antman, 2008, Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention a TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction) analysis, J Am Coll Cardiol, 51, 2028, 10.1016/j.jacc.2008.04.002 Aubert, 2008, Proton pump inhibitors effect on clopidogrel effectiveness: The Clopidogrel Medco Outcomes Study (Abstract), Circulation, 118, S_815, 10.1161/circ.118.suppl_18.S_815 Bhatt, 2008, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use, Circulation, 118, 1894, 10.1161/CIRCULATIONAHA.108.191087 Blagojevic, 2009, Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study, Pharmacoepidemiol Drug Saf, 18, 362, 10.1002/pds.1716 Brandt, 2007, Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel, J Thromb Haemost, 5, 2429, 10.1111/j.1538-7836.2007.02775.x Brophy, 2006, A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention, Am Heart J, 152, 263, 10.1016/j.ahj.2005.08.023 Buonamici, 2007, Impact of platelet reactivity after clopidogrel administration on drug-eluting stentthrombosis, J Am Coll Cardiol, 49, 2312, 10.1016/j.jacc.2007.01.094 Cannon, 2004, PROVE-IT-TIMI 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 CAPRIE Steering Committee, 1996, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet, 348, 1329, 10.1016/S0140-6736(96)09457-3 Clarke, 2003, The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin, Drug Metab Dispos, 31, 53, 10.1124/dmd.31.1.53 Collet, 2009, Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study, Lancet, 373(, 309, 10.1016/S0140-6736(08)61845-0 Dunn, 2008, Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial, Circulation, 118, 815A, 10.1161/circ.118.suppl_18.S_815-a Ernesto, 2007, Clopidogrel resistance, Heart Lung Circ, 16, S17 Evans, 2003, Pharmacogenomics: Drug disposition, drug targets, and side effects, N Engl J Med, 348, 538, 10.1056/NEJMra020526 Farid, 2007, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently, Clin Pharmacol Ther, 81, 735, 10.1038/sj.clpt.6100139 Frere, 2008, Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome, Am J Cardiol, 101, 1088, 10.1016/j.amjcard.2007.11.065 Fontana, 2007, Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects, J Thromb Haemost, 5, 2153, 10.1111/j.1538-7836.2007.02722.x Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064 Gilard, 2006, Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin, J Thromb Haemost, 4, 2508, 10.1111/j.1538-7836.2006.02162.x Giusti, 2007, Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients, Pharmacogenet Genomics, 17, 1057, 10.1097/FPC.0b013e3282f1b2be Giusti, 2009, Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis, Am J Cardiol, 103, 806, 10.1016/j.amjcard.2008.11.048 Gurbel, 2005, The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting, J Am Coll Cardiol, 45, 1392, 10.1016/j.jacc.2005.01.030 Gurbel, 2003, Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83 Gurbel, 2005, Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results from the CREST Study, J Am Coll Cardiol, 46, 1827, 10.1016/j.jacc.2005.07.056 Gurbel, 2003, Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial, Am Heart J, 145, 239, 10.1067/mhj.2003.109 Han, 2009, A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation, Chin Med J, 122, 793 Herbert, 2003, P2Y12, a new platelet ADP receptor, target of clopidogrel, Semin Vasc Med, 3, 113, 10.1055/s-2003-40669 Ho, 2009, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome, JAMA, 301, 937, 10.1001/jama.2009.261 Hochholzer, 2006, Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement, J Am Coll Cardiol, 48, 1742, 10.1016/j.jacc.2006.06.065 Hochholzer, 2005, Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention, Circulation, 111, 2560, 10.1161/01.CIR.0000160869.75810.98 Horn, 2004, Review article: Relationship between the metabolism and efficacy of proton pump inhibitors — Focus on rabeprazole, Aliment Pharmacol Ther, 20, 11, 10.1111/j.1365-2036.2004.02161.x Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052 Ishizaki, 1999, Review article: cytochrome P450 and the metabolism of proton pump inhibitors — Emphasis on rabeprazole, Aliment Pharmacol Ther, 13, 27, 10.1046/j.1365-2036.1999.00022.x Iakovou, 2005, Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents, JAMA, 293, 2126, 10.1001/jama.293.17.2126 Jeremias, 2004, Stent thrombosis after successful sirolimus-eluting stent implantation, Circulation, 109, 1930, 10.1161/01.CIR.0000127105.99982.21 Juurlink, 2009, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel, CMAJ, 180, 713, 10.1503/cmaj.082001 Kim, 2008, The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance, Clin Pharmacol Ther, 84, 236, 10.1038/clpt.2008.20 Kim, 2008, Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects, Eur J Clin Pharmacol, 64, 589, 10.1007/s00228-008-0471-0 King, 2007, Focused update of the ACC/ AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Circulation, 117, 261, 10.1161/CIRCULATIONAHA.107.188208 Kuehl, 2001, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat Genet, 27, 383, 10.1038/86882 Lau, 2004, Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance, Circulation, 109, 166, 10.1161/01.CIR.0000112378.09325.F9 Lau, 2003, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug–drug interaction, Circulation, 107, 32, 10.1161/01.CIR.0000047060.60595.CC Le Breton, 1996, Role of platelets in restenosis after percutaneous coronary revascularization, J Am Coll Cardiol, 28, 1643, 10.1016/S0735-1097(96)00417-2 Lim, 2005, Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: Perspectives from a large multinational registry, Eur Heart J, 26, 1063, 10.1093/eurheartj/ehi139 Marteau, 2003, Pharmacological characterization of the human P2Y13 receptor, Mol Pharmacol, 64, 104, 10.1124/mol.64.1.104 Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic vents in patients with acute myocardial infarction, Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03 Mega, 2009, Cytochrome P-450 polymorphisms and response to clopidogrel, N Engl J Med, 360, 354, 10.1056/NEJMoa0809171 Michelson, 2009, Methods for the measurement of platelet function, Am J Cardiol, 103, 20A, 10.1016/j.amjcard.2008.11.019 Michelson, 2006, Current options in platelet function testing, Am J Cardiol, 98, 4N, 10.1016/j.amjcard.2006.09.008 Mitsios, 2004, Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5weeks in patients with acute coronary syndromes, Circulation, 109, 1335, 10.1161/01.CIR.0000124581.18191.15 Müller, 2003, Effects of statins on platelet inhibition by a high loading dose of clopidogrel, Circulation, 108, 2195, 10.1161/01.CIR.0000099507.32936.C0 Müller, 2001, Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement, Heart, 85, 92, 10.1136/heart.85.1.92 Mukherjee, 2005, Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome, Heart, 91, 23, 10.1136/hrt.2004.035014 Nebert, 2002, Clinical importance of the cytochromes P450, Lancet, 360, 1155, 10.1016/S0140-6736(02)11203-7 Neubauer, 2003, Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study, Eur Heart J, 24, 1744, 10.1016/S0195-668X(03)00442-1 Nguyen, 2005, Resistance to clopidogrel: A review of the evidence, J Am Coll Cardiol, 45, 1157, 10.1016/j.jacc.2005.01.034 O'Donoghue, 2006, Clopidogrel response variability and future therapies: Clopidogrel: Does one size fit all?, Circulation, 114, e600, 10.1161/CIRCULATIONAHA.106.643171 O'Donoghue, 2009, Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials, Lancet, 374, 989, 10.1016/S0140-6736(09)61525-7 Pereillo, 2001, Structure and stereochemistry of the active metabolite of clopidogrel, Drug Metab Dispos, 30, 1288, 10.1124/dmd.30.11.1288 Pinto Slottow, 2009, Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis, Am J Cardiol, 104, 525, 10.1016/j.amjcard.2009.04.015 Savi, 1998, Role of P2Y1 purinoceptor in ADP-induced platelet activation, FEBS Lett, 422, 291, 10.1016/S0014-5793(98)00025-8 Savi, 1994, The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A, Thromb Haemost, 72, 313, 10.1055/s-0038-1648859 Savi, 1992, Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel, Biochem Pharmacol, 44, 527, 10.1016/0006-2952(92)90445-O Savi, 2001, P2y(12), a new platelet ADP receptor, target of clopidogrel, Biochem Biophys Res Commun, 283, 379, 10.1006/bbrc.2001.4816 Savi, 1998, Clopidogrel: A review of its mechanism of action, Platelets, 9, 251, 10.1080/09537109876799 Savi, 2006, The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts, Proc Natl Acad Sci U S A, 103, 11069, 10.1073/pnas.0510446103 Saw, 2007, Lack of evidence of a clopidogrel–statin interaction in the CHARISMA trial, J Am Coll Cardiol, 50, 291, 10.1016/j.jacc.2007.01.097 Saw, 2003, Lack of adverse clopidogrel atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial, Circulation, 108, 921, 10.1161/01.CIR.0000088780.57432.43 Sibbing, 2009, Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention, Eur Heart J, 30, 916, 10.1093/eurheartj/ehp041 Silber, 2005, Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology, Eur Heart J, 26, 804, 10.1093/eurheartj/ehi138 Siller-Matula, 2008, Calcium-channel blockers reduce the antiplatelet effect of clopidogrel, J Am Coll Cardiol, 52, 1557, 10.1016/j.jacc.2008.07.055 Siller-Matula, 2009, Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel, Am Heart J, 157, 148.e1-5, 10.1016/j.ahj.2008.09.017 Simon, 2009, Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, 363, 10.1056/NEJMoa0808227 Smith, 2006, AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute, Circulation, 113, 2363, 10.1161/CIRCULATIONAHA.106.174516 Smith, 2006, Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy, Platelets, 17, 250, 10.1080/09537100500475844 Spertus, 2006, Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry, Circulation, 113, 2803, 10.1161/CIRCULATIONAHA.106.618066 Steinhubl, 2005, The role of the platelet in the pathogenesis of atherothrombosis, Am J Cardiovasc Drugs, 5, 399, 10.2165/00129784-200505060-00007 Suh, 2006, Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel, CMAJ, 174, 1715, 10.1503/cmaj.060664 Tan, 2009, Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention, Cardiovasc Revasc Med, 36, 10.1016/j.carrev.2008.11.001 Thebault, 1999, Single-dose pharmacodynamics of clopidogrel, Semin Thromb Hemost, 25, 3 Thebault, 1999, Repeated dose pharmacodynamics of clopidogrel in healthy subjects, Semin Thromb Hemost, 25, 9 Trenk, 2008, Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents, J Am Coll Cardiol, 51, 1925, 10.1016/j.jacc.2007.12.056 Trenk, 2008, Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement, Thromb Haemost, 99, 174, 10.1160/TH07-08-0503 Umemura, 2008, The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects, J Thromb Haemost, 6, 1439, 10.1111/j.1538-7836.2008.03050.x Vinholt, 2005, The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease, Thromb Haemost, 94, 438, 10.1160/TH05-01-0046 Von Beckerath, 2005, Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial, Circulation, 112, 2946, 10.1161/CIRCULATIONAHA.105.559088 Von Beckerath, 2005, P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphateinduced platelet aggregation after initiation of clopidogrel therapy with a high loading dose, Blood Coagul Fibrinolysis, 16, 199, 10.1097/01.mbc.0000164429.21040.0a Wallentin, 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 361, 1045, 10.1056/NEJMoa0904327 Wang, 2006, Aspirin and clopidogrel resistance: an emerging clinical entity, Eur Heart J, 27, 647, 10.1093/eurheartj/ehi684 Wienbergen, 2003, Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin, Am J Cardiol, 92, 285, 10.1016/S0002-9149(03)00626-X Wilkinson, 2005, Drug metabolism and variability among patients in drug response, N Engl J Med, 352, 2211, 10.1056/NEJMra032424 Wiviott, 2008, Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITONTIMI 38 trial: A subanalysis of a randomised trial, Lancet, 371, 1353, 10.1016/S0140-6736(08)60422-5 Wiviott, 2007, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, 2001, 10.1056/NEJMoa0706482 Wiviott, 2007, Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial, Circulation, 116, 2923, 10.1161/CIRCULATIONAHA.107.740324 Woulfe, 2001, ADP and platelets: The end of the beginning, J Clin Invest, 107, 1503, 10.1172/JCI13361 Wrighton, 2001, The human CYP3A subfamily: Practical considerations, Drug Metab Rev, 32, 339